885273-73-4

Basic information

• Product Name: (1H-INDOL-6-YL)-CARBAMIC ACID TERT-BUTYL ESTER
• Synonyms: 6-BOC-AMINO-1H-INDOLE;(1H-INDOL-6-YL)-CARBAMIC ACID TERT-BUTYL ESTER;CarbaMicacid,1H-indol-6-yl-,1,1-diMethylethylester;Carbamic acid, N-1H-indol-6-yl-, 1,1-dimethylethyl ester
• CAS NO: 885273-73-4
• Molecular Formula: C₁₃H₁₆N₂O₂
• Molecular Weight: 232.28
• Mol File: 885273-73-4.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (1H-INDOL-6-YL)-CARBAMIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: (1H-INDOL-6-YL)-CARBAMIC ACID TERT-BUTYL ESTER(885273-73-4)
• EPA Substance Registry System: (1H-INDOL-6-YL)-CARBAMIC ACID TERT-BUTYL ESTER(885273-73-4)

Safety Data

• Hazardous Substances Data: 885273-73-4(Hazardous Substances Data)

Usage

General Description

"(1H-INDOL-6-YL)-CARBAMIC ACID TERT-BUTYL ESTER" is a chemical compound that belongs to the class of tert-butyl carbamates. It is derived from 1H-indole-6-carboxylic acid and is commonly used in the pharmaceutical industry for the synthesis of various drugs and biologically active compounds. The tert-butyl ester group in the compound provides stability and protection to the indole ring, making it a useful intermediate in organic synthesis. (1H-INDOL-6-YL)-CARBAMIC ACID TERT-BUTYL ESTER has attracted attention for its potential pharmacological activities and has been studied for its anti-inflammatory, anticancer, and antimicrobial properties. Its unique structure and functional groups make it a valuable building block in drug discovery and development.

Upstream product

• 5318-27-4 6-amino-1H-indole 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 1414628-64-0 C₂₃H₂₇N₃O₃S 
• 1414628-94-6 C₂₂H₂₃N₃O₂ 
• 1414629-00-7 C₂₃H₂₅N₃O₄S 
• 1414628-41-3 tert-butyl [3-(2-(4-benzylpiperidin)acetyl)-1H-indol-5-yl]carbamate 
• 1414628-86-6 1-[(tert-butyl-1H-indol-6-yl-carbamate)4-benzilpiperdin-1-yl]-2-oxoethanone 
• 1414628-54-8 C₂₂H₂₅N₃O 
• 1421589-49-2 3-(4-ethoxyphenyl)-N-[(4-ethylphenyl)methyl]-1H-indol-6-amine 
• 1549940-57-9 tert-butyl 3-[2-(4-(4-fluorobenzyl)piperidin-1-yl)acetyl]-1H-indol-6-ylcarbamate 
• 1549940-74-0 tert-butyl 3-(2-(4-(4-fluorobenzyl)piperidin-1-yl)-2-oxoacetyl)-1H-indol-6-ylcarbamate 
• 1549940-86-4 1-(6-amino-1H-indol-3-yl)-2-(4-(4-fluorobenzyl)piperidin-1-yl)ethanone 
• 1549940-92-2 1-(6-amino-1H-indol-3-yl)-2-(4-(4-fluorobenzyl)piperidin-1-yl)ethane-1,2-dione 
• 1549940-95-5 N-(3-(2-(4-(4-fluorobenzyl)piperidin-1-yl)acetyl)-1H-indol-6-yl)methanesulfonamide 
• 1549940-97-7 N-(3-(2-(4-(4-fluorobenzyl)piperidin-1-yl)-2-oxoacetyl)-1H-indol-6-yl)methanesulfonamide 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER

The application relates to heterocyclic amide derivatives and their use in the treatment and prophylaxis of cancer, and to compositions containing said derivatives and processes for their preparation. (Formula (I))

ANTIVIRAL DRUGS FOR TREATMENT OF ARENA VIRUS INFECTION

Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by the Arenavirus family such as Lassa fever, Argentine hemorrhagic fever, Bolivian hemorrhagic fever, and Venezuelan hemorrhagic fever

Evaluation and target validation of indole derivatives as inhibitors of the AcrAB-TolC efflux pump

Indole derivatives 3-amino-6-carboxyl-indole and 3-nitro-6-amino-indole were designed and synthesized based on the TolC structure. They proved to have potent synergistic antibacterial effects on chloramphenicol, tetracycline, erythromycin, and ciprofloxacin against Escherichia coli YD2 and FJ307 with decreased minimal inhibitory concentrations (MICs) at 2-64 folds. To research its functional site, Escherichia coli BL21(DE3)-3 expressing a target-site mutated TolC was constructed by red homologous recombination and the site-directed mutagenesis technique. They did not noticeably affect antimicrobial activity against BL21(DE3)-3. All the results indicate that these compounds match our design and can be developed as efflux pump inhibitors for the AcrAB-TolC efflux pump.